Segall Bryant & Hamill LLC Trims Holdings in Galapagos NV (NASDAQ:GLPG)

Segall Bryant & Hamill LLC reduced its holdings in shares of Galapagos NV (NASDAQ:GLPG) by 11.7% during the 3rd quarter, HoldingsChannel reports. The firm owned 705,648 shares of the biotechnology company’s stock after selling 93,431 shares during the period. Segall Bryant & Hamill LLC’s holdings in Galapagos were worth $20,316,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of the business. Headlands Technologies LLC lifted its holdings in shares of Galapagos by 56.7% during the second quarter. Headlands Technologies LLC now owns 1,233 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 446 shares during the period. GAMMA Investing LLC increased its position in Galapagos by 140.7% during the 3rd quarter. GAMMA Investing LLC now owns 1,259 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 736 shares during the period. Rhumbline Advisers raised its stake in shares of Galapagos by 21.6% during the 2nd quarter. Rhumbline Advisers now owns 4,578 shares of the biotechnology company’s stock worth $113,000 after buying an additional 814 shares in the last quarter. Signaturefd LLC lifted its holdings in shares of Galapagos by 48.1% in the 2nd quarter. Signaturefd LLC now owns 3,872 shares of the biotechnology company’s stock valued at $96,000 after buying an additional 1,258 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of Galapagos by 63.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 3,899 shares of the biotechnology company’s stock valued at $112,000 after buying an additional 1,510 shares in the last quarter. 32.46% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have commented on GLPG. Kepler Capital Markets downgraded Galapagos from a “hold” rating to a “reduce” rating in a report on Wednesday. Leerink Partners started coverage on Galapagos in a research note on Monday, September 9th. They set a “market perform” rating and a $24.00 price target on the stock. Raymond James downgraded Galapagos from an “outperform” rating to a “market perform” rating in a research note on Friday, August 2nd. Royal Bank of Canada decreased their target price on Galapagos from $32.00 to $30.00 and set a “sector perform” rating on the stock in a research report on Friday, November 1st. Finally, Leerink Partnrs upgraded Galapagos to a “hold” rating in a research report on Monday, September 9th. Two equities research analysts have rated the stock with a sell rating and six have given a hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $30.75.

Galapagos Stock Down 3.9 %

Galapagos stock opened at $25.64 on Thursday. Galapagos NV has a 12-month low of $24.16 and a 12-month high of $42.46. The firm’s 50-day moving average is $28.76 and its two-hundred day moving average is $27.54.

Galapagos Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.